Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. April 2026 18:14 ET | Quelle: AgomAb Therapeutics NV

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Agomab Therapeutics NV today reported financial results for the full year period ended December 31, 2025, and confirmed its outlook for 2026.
26. März 2026 07:00 ET | Quelle: AgomAb Therapeutics N.V.

Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis

Agomab today announced that the USPTO granted a patent covering the composition of matter of AGMB-447.
08. Januar 2026 05:00 ET | Quelle: AgomAb Therapeutics N.V.

Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort

Agomab today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants.